Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis (iPROACT-MS)
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
• Women and men ≥18 and ≤65 years of age
• Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates)
• Routinely treated and monitored for MS
• Speak and read Danish
• Deemed physically and mentally able to participate in this study